Biocartis Nabs FDA 510(k) Clearance for Lynch Syndrome Screening Assay
The Idylla MSI Test identifies microsatellite instability in colorectal cancer tumors to aid in the identification of potential Lynch syndrome.
Intermountain Builds Up Bioinformatics to Make HerediGene Sequencing Data Clinically Actionable
The health system, which has now enrolled 150,000 people in its population genomics program, has implemented its technology across CDC tier one conditions but has grander ambitions.
Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer
The assay is intended to detect
Invitae to Provide Genetic Testing Within eMERGE Population Screening Study
As a new clinical affiliate, Invitae will test up to 25,000 patients in a study exploring the role of genetics in cancer, heart disease, and other conditions.
Researchers Aim to Improve Lynch Syndrome Testing With Genetic-Epigenetic Combination Method
The sequencing test involves a single library preparation that is then split for parallel analysis of promoter methylation, MSI calculation, and gene mutation detection.